Business Wire

NY-IMPACTWAYV

9.3.2021 15:02:11 CET | Business Wire | Press release

Share
ImpactWayv™ Completes Beta Test of Its Social Impact Media and Technology Platform and Announces Upcoming Public Launch

ImpactWayv, Inc. is pleased to announce it has recently concluded the private beta test of ImpactWayv ™, the company’s pioneering social impact media and technology networking platform that will launch publicly this spring. ImpactWayv connects people, businesses and philanthropy – for good.

Designed to be a healthier and more meaningful alternative to major social networking platforms, ImpactWayv is the next generation digital ecosystem where people, businesses and nonprofits engage to effect positive change and maximize social impact. ImpactWayv unites disparate sources of information, initiatives and innovations from across the global social good sector under one digital roof to generate greater and more efficient collective impact.

Reception to ImpactWayv’s invitation-only private beta test was overwhelmingly positive, with individual, business and nonprofit users confirming the strong need for this type of holistic social impact-focused platform within today’s social media landscape. Users were guided through ImpactWayv’s core user flow to validate design, functionality and usability. The results reinforced the platform’s underlying social impact thesis, focused on fostering universal social good through a continuous cycle of engagement, interaction and empowerment.

At a time of unprecedented interest in social action globally, ImpactWayv provides the social media network solution that addresses the convergence of three major trends in society:

  • People’s hunger for greater purpose and meaning in all aspects of life – family, friends, social interaction, employment, consumer relationships, investing, donating and volunteering.
  • Businesses’ imperative to demonstrate to all stakeholders and the world their social good efforts.
  • Nonprofits’ pressing need for global connectivity and adoption of private sector business and marketing principles, supporting sustainability and mission achievement.

“ImpactWayv is uniquely positioned for this moment in time,” said George Dolatly, Co-Founder and President of ImpactWayv, Inc. “Our groundbreaking platform creates the opportunity for people, businesses and nonprofits to work together efficiently and effectively on all fronts to maximize social good and positive change.”

ImpactWayv will also feature a digital “Social Impact as a Service” (SIaaS) offering to both businesses and nonprofits to best address emerging social impact trends such as business models that integrate the values and metrics of Environmental, Social & Governance (ESG) criteria, Corporate Social Responsibility (CSR) and the United Nations Sustainable Development Goals (SDGs). This will allow ImpactWayv to provide advisory and support services through a global team of social impact sector leaders, experts and experienced professionals.

“Our current climate has demonstrated just how motivated people are to come together to foster positive social change,” said Benji Bernstein, Co-Founder and Chief Technology Officer of ImpactWayv, Inc. “The time is now for a new digital ecosystem that meets this critical moment – a social media network created to unite and empower people, businesses and nonprofits for greater collective impact, via a continuous cycle of social good. ImpactWayv is that platform, a breakthrough force for good.”

About ImpactWayv, Inc.

ImpactWayv, Inc. is a social impact media and technology company, consisting of thought leaders and doers from across the business, nonprofit and technology sectors. ImpactWayv was created to disrupt and transform the worlds of business and philanthropy through technology – to advance universal social good. For more information or to be added to the ImpactWayv user list, please visit: www.ImpactWayv.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye